Precision psychiatry promises to more accurately diagnose and treat patients. Brain health experts call for European researchers, policymakers and industry to work together to advance the field and give Europe a competitive edge.
Marion Leboyer, Paweł Świeboda, Harris A. Eyre, Veronique Briquet-LaugierJune 5, 2023
Hostile immigration enforcement policies and anti-immigrant actions against refugees and asylum seekers are causing trauma to migrant families and exposing them to dangerous living conditions on both sides of the U.S.-Mexico border.
Luz Maria Garcini, Kimberly Nguyen, Daniel Argueta, Aldo Barrita, Amy Barrett, Jin YanMay 25, 2023
A well-managed U.S.-Mexico border is essential not only for millions of border residents in both countries, but for the U.S. economy and federal budget. This brief lays out recommendations to strengthen the institutional scaffolding that could allow for a safer and more prosperous North American continent.
Continued robust economic growth in the U.S. will, among many other things, require policies that encourage rapid technological innovation and increases in productivity, promote investment while reducing debt, and maximize economic efficiency. The authors explain why in this brief.
The authors argue for an identification and tax program that would allow unauthorized residents to receive identification documents and reside and work legally in the United States. In return, they would pay taxes much like any other American.
Mexico's government has eliminated almost all conditions (health checkups, school attendance for children) previously attached to cash transfers for the poor. The author considers the impact of the antipoverty overhaul.
With growing competition from abroad, the U.S. must reform its fiscal policy to reduce debt, maximize economic efficiency — including minimizing the distortions caused by the tax system — and maintain its areas of competitive advantage.
The human papillomavirus (HPV) affects over 80 million Americans, causing more than 40,000 cases of HPV-associated cancers in the U.S. In 2006, the FDA licensed the first HPV vaccine, which could help save thousands of lives; no cure for HPV currently exists. However, the political controversy raised by the vaccine has limited its acceptance and use. Such resistance potentially jeopardizes an opportunity to reduce cancer rates in Texas and the broader United States.
Kirstin R.W. Matthews, Monica M. MatsumotoOctober 6, 2014